Active Ingredient(s): Polatuzumab Vedotin-piiq
FDA Approved: * June 10, 2019
Pharm Company: * GENENTECH

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Polivy Overview

Polatuzumab vedotin (INN;[4] brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer.[5] The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.[6][7] The drug was developed by Genentech and Roche.[not verified in body] History In June 2019, polatuz...

Read more Polivy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Polatuzumab_vedotin

Recent Polivy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Polatuzumab Vedotin-piiq
  • Injection: 140mg
  • Powder: 140mg/vial, 30mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Polivy: (2 results)

Sorted by National Drug Code
  • 50242-103 Polivy 30 mg/1.88ml Intravenous Injection, Powder, Lyophilized, for Solution by Genentech, Inc.
  • 50242-105 Polivy 140 mg/7.52ml Intravenous Injection, Powder, Lyophilized, for Solution by Genentech, Inc.

Other drugs which contain Polatuzumab Vedotin-piiq or a similar ingredient: (1 result)